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Abstract
CB2R receptors have demonstrated beneficial effects in wound healing in several models. We 
therefore investigated a potential role of CB2R receptors in corneal wound healing. We examined 
the functional contribution of CB2R receptors to the course of wound closure in an in vivo murine 
model. We additionally examined corneal expression of CB2R receptors in mouse and the 
consequences of their activation on cellular signaling, migration and proliferation in cultured 
bovine corneal epithelial cells (CECs). Using a novel mouse model, we provide evidence that 
corneal injury increases CB2R receptor expression in cornea. The CB2R agonist JWH133 induces 
chemorepulsion in cultured bovine CECs but does not alter CEC proliferation. The signaling 
profile of CB2R activation is activating MAPK and increasing cAMP accumulation, the latter 
perhaps due to Gs-coupling. Lipidomic analysis in bovine cornea shows a rise in 
acylethanolamines including the endocannabinoid anandamide 1 hour after injury. In vivo, CB2R 
deletion and pharmacological block result in a delayed course of wound closure. In summary, we 
find evidence that CB2R receptor promoter activity is increased by corneal injury and that these 
receptors are required for the normal course of wound closure, possibly via chemorepulsion.
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Cannabinoid receptors were once chiefly known as the endogenous target for the 
psychoactive ingredients of marijuana (Gaoni and Mechoulam, 1964). However, it is now 
appreciated that the endogenous cannabinoid signaling system is important in its own right, 
playing physiological roles in pain, neurodegeneration, appetite and energy regulation, 
learning and memory, addiction, bone homeostasis and remodeling, cancer, immune 
function, cardiovascular function, and reproduction (Howlett et al., 2004; Kano et al., 2009). 
Cannabinoids are also active in the eye, where CB1R receptors are widely expressed 
(Straiker et al., 1999a; Straiker et al., 1999b). CB1R activation alters intraocular pressure, 
iridial contraction and perhaps vision (reviewed in (Cairns et al., 2015)). Deleterious 
mutations of the endocannabinoid-metabolizing enzyme ABHD12 in humans result in the 
development of cataracts and retinal degeneration (Fiskerstrand et al., 2010). CB1R 
receptors are abundant in human corneal epithelial cells (CECs) (Straiker et al., 1999b) and 
mediate chemotaxis in cultured bovine CECs (Murataeva et al., 2016). Importantly, CB1R 
deletion slows wound healing (Yang et al., 2013), suggesting that cannabinoids, via CB1R, 
regulate the rate of wound closure via a chemotaxic mechanism, using an endocannabinoid 
gradient to provide directional cues to CECs during the healing process (Murataeva et al., 
2015).
CB2R receptors were identified shortly after CB1R (Munro et al., 1993) but the data on 
ocular CB2R has been mixed: most receptor expression studies have not detected CB2R in 
the anterior eye (Buckley et al., 1998; Lu et al., 2000; Porcella et al., 1998; Porcella et al., 
2000), but a few pharmacological studies provide evidence for functional CB2R in the eye 
(He and Song, 2007; Zhong et al., 2005). Cannabinoid pharmacology can however be 
problematic; we have shown for instance that CB2R agonist JWH015 (used in (He and 
Song, 2007; Zhong et al., 2005)) is also a potent and efficacious CB1R agonist (Murataeva 
et al., 2012).
CB2R receptors have demonstrated beneficial effects in wound healing in several models (Li 
et al., 2016; Wang et al., 2016; Wright et al., 2005; Zheng et al., 2012) and been shown to 
regulate chemotaxis in immune-related cells such as lymphocytes (e.g. (Ghosh et al., 2006)). 
The current study investigates CB2R upregulation upon corneal injury and its role in corneal 
wound healing.
2 MATERIAL AND METHODS
2.1 Animals
Experiments were conducted at the Indiana University campus. All mice used for 
experiments were handled according to the guidelines of the Indiana University animal care 
committee and in accordance with the ARVO animal statement. Mice (age 3–8 months) 
were kept on a 12 h (06:00–18:00) light dark cycle, and fed ad libitum. Male and female 
C57BL/6J (C57) and CD1 strain mice were kindly provided by Dr. Ken Mackie (Indiana 
University, Bloomington IN). Mice were allowed to acclimatize to the animal care facility 
for at least a week prior to their use in experiments. CB1R KO and CB2R KO mice were 
kindly provided by Dr. Ken Mackie. The KOs are all global KOs. CB1R KO animals were 
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originally received from Dr. Catherine Ledent (Catholic University, Leuven) as 
heterozygotes (Ledent et al., 1999). The CB2R KO mice were originally purchased from 
Jackson Labs (Bar Harbor, ME).
2.2 Generation of CB2R-GFP Reporter Mice
Generation of CB2R-GFP reporter mice has been described (Lopez et al., 2018, In Press). 
Briefly an eGFP reporter gene preceded by an IRES sequence was inserted into the 3’ UTR 
of the cnr2, (CB2R) gene into the embryonic stem cells of C57BL/6j mice. This resulted in 
the expression of floxed eGFP under the control of the endogenous mouse CB2R promoter. 
The mouse model (CB2R eGFP/f/f) was generated by homologous recombination in 
embryonic stem cells, in the C57BL/6J genetic background.
2.3 Bovine Corneal Epithelial Cell culture
Bovine CECs (bCECs) were harvested from cow eyes obtained from healthy animals of the 
species Bos primigenius taurus at a local farm. bCECs were dissociated with a combination 
of trypsin (0.25%) treatment and scraping. Cells were then grown in SHEM media 
containing DMEM (44%), F-12 (44%), fetal bovine serum (10%), penicillin/streptomycin 
(1%), amphotericin (2.5 μg/mL), insulin (5 μg/mL), EGF (5 ng/mL). Note that in contrast to 
our previous study (Murataeva et al., 2015) we avoided the use of DMSO in this SHEM 
media. Cells received a media change every third day and were subcultured once the flask 
reached 75% confluence. Cells were not cultured past the third passage.
2.4 Immunohistochemistry
For immunohistochemistry, mouse eyes were fixed in 4% paraformaldehyde for 45 mins at 
4 °C, then placed sequentially in 10% and 30% sucrose in PBS overnight before being 
quick-frozen in OCT. Fixed eyes were sectioned on a Leica cryostat, then sections were 
mounted on Superfrost plus slides. Slides were blocked with BSA, followed by treatment 
with primary antibodies (in PBS, saponin, 0.2%) for 1–2 days at 4°C. In cases where 
secondary antibodies were required, a second staining with secondary antibody (~4 hrs at 
RT) was done after washing off the primary antibody. Primary antibodies were Anti-GFP 
(Prelabeled with Alexa647; Thermo Scientific, A-31852), phalloidin preconjugated to 
Alexa488 (Thermo Scientific, cat#: A12379), and Laminin-5 (AB14509, Abcam) followed 
by Alexa647 anti-rabbit (A-150075, Thermo Scientific). Slides were then mounted 
(Fluoromount, Sigma-Aldrich, St. Louis, MO) and coverslipped to prepare for imaging. 
Images were acquired with a Leica TCS SP5 confocal microscope (Leica Microsystems, 
Wetzlar, Germany) using Leica LAS AF software and a 63X oil objective. Images were 
processed using ImageJ (available at http://rsbweb.nih.gov/ij/) and/or Photoshop (Adobe 
Inc., San Jose, CA). Images were modified only in terms of brightness and contrast.
2.5 Cell proliferation assay
bCECs were plated at a concentration of 10000 cells/well in a 96 well plate in serum-free 
SHEM medium. After 30 hours incubation under various treatment conditions, the cells 
were labeled with nuclear marker DRAQ5, the slides were imaged on an Odyssey scanner 
(LiCOR Biosciences, Lincoln, NE).
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Cyclase assays: Cyclase assays were optimized using Perkin Elmer’s LANCE® Ultra 
cAMP kit (Catalog # TRF0262, Perkin Elmer, Boston, MA) following the manufacturer’s 
instruction. All assays were performed at room temperature using 384-optiplates (Catalog# 
6007299, Perkin Elmer). Briefly, cells were resuspended in 1X stimulation buffer (1X 
Hank’s Balanced Salt Solution (HBSS), 5 mM HEPES, 0.5 mM IBMX, 0.1% BSA, pH 7.4, 
made fresh on the day of experiment). Cells (10 μL/well; 5000 cells/well) were incubated for 
1 hour at 37° C, 5% CO2 and humidified air and then transferred to a 384-optiplate (500 
cells/μl, 10μl), followed by stimulation with drugs/compounds made in 1X stimulation 
buffer as appropriate, for 10 mins. Cells were then lysed by addition of 10μl Eu-cAMP tracer 
working solution (4X, made fresh in 1X lysis buffer supplied with the kit; under subdued 
light conditions) and 10μl Ulight™ anticAMP working solution (4X, made fresh in 1X lysis 
buffer) and further incubated for 1 hour at room temperature. Plates were then read with the 
TR FRET mode on an Enspire plate reader (Perkin Elmer, Boston, MA).
MAPK assay: Cells were plated at 75000 cells/well on poly-D-lysine coated 96 well plates 
overnight in serum-free conditions (37° C, 5% CO2, humidified air). The following day, 
cells were challenged with compounds made in serum-free media for 5 mins. Cells were 
fixed in 4% PFA for 30 mins followed by further 15 min incubation with methanol at −20° 
C. Plates were washed with TBS/0.1% Triton X-100 for 25 mins (5 × 5 min washes). The 
wash solution was then replaced by Odyssey blocking buffer and incubated further for 90 
min with gentle shaking at room temperature. Blocking solution was removed and replaced 
with blocking solution containing anti-phospho-ERK½ antibody (1:150; Cell Signaling 
Technology®, Danvers, MA); antibody exposure occurred overnight with shaking at 4°C. 
The next day, plates were washed with TBS containing 0.05% Tween-20 for 25 min (5 × 5 
min washes). Secondary antibody, donkey anti-rabbit conjugated with IR800 dye (Rockland, 
Limerick, PA), prepared in blocking solution, was added and gently shaken for 1 hour at 
room temperature. The plates were then again washed 5 times with TBS/0.05% Tween-20 
solution. The plates were patted dry and scanned using LI-COR Odyssey scanner. pERK½ 
activation (expressed in %) was calculated by dividing average integrated intensities of the 
drug treated wells by average integrated intensities of vehicle-treated wells. All assays were 
performed in triplicate, unless otherwise stated.
2.7 Live-imaging migration assay
In vitro cell migration was also visualized using an upright Nikon E800 microscope fitted 
with a Hamamatsu Orca-ER camera and Metamorph acquisition software. The microscope 
was housed in an environmental chamber that regulated temperature (33° C), and pH by 
streaming humidified carbogen over the samples. This whole apparatus was covered in a 
grounded Faraday cage. Images were acquired using a 4x objective over the course of an 
hour at 10-second intervals. Cells were tracked using the mTrackJ software plugin 
(Meijering et al., 2012) for ImageJ (http://www.imagescience.org/meijering/software/
mtrackj/). JWH133 was embedded in 1.5% agar prepared from serum-free media on the day 
of the experiment. Cells were maintained in serum-free media overnight before plating into 
60mm petri dishes coated with poly-D-lysine. Movement of cells within the dish was 
monitored before and after placement of a cube (<1 cm3) of drug- embedded agar at the 
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edge of the dish. The location of the agar cube was varied to address the possibility of 
migration due to other environmental factors such as electric fields. The concentration of 
JWH133 was chosen based on our Boyden Chamber-derived concentration-responses for 
WIN55212 and 2-AG (Murataeva et al., 2015).
2.8 In vivo corneal wound healing study.
A ~ 1 mm diameter circular axial corneal epithelial defect was created in an isoflurane-
anesthetized mouse using an Alger Brush under a stereomicroscope. We used mechanical 
debridement, a method similar to that used by Yang et al. (Yang et al., 2013), but with 
distinctions regarding the size of the wound and the interval of monitoring the healing 
process. When drugs (JWH133, SR144528) were applied, these were dissolved in Tocrisolve 
then applied as 5uL drops to the eyes of C57 mice after injury but while animal was still 
anesthetized. The mouse was briefly re-anesthetized with isoflurane at 3 hour intervals to 
monitor the progress of corneal wound healing. Wound area was measured by staining the 
eye with fluorescein (0.2 mg/mL in PBS) and was illuminated with a blue-violet light source 
and photographed using a camera-mounted stereomicroscope. Wound area was quantified 
using ImageJ. The basement membrane is intact after wounding as demonstrated by 
Laminin-5 staining (Supplementary Figure 1).
2.9 Quantitative RT-PCR
Primers for selected components of the endocannabinoid system were designed using 
Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast) and the corresponding mouse 
gene. Primer sequences are as listed,
msCB1R S: 5′ - CTG ATC CTG GTG GTG TTG ATC ATC TG 3′
msCB1R AS: 5′ - CGT GTC TGT GGA CAC AGA CAT GGT 3′
msCB2R S: 5′ - AAA GCA AGG AGG TCC ACT CG 3′
msCB2R AS: 5′ - GCC GTT GAC CTT CAC AGA GA 3′
msGPR18-S 5′- CAG CCT TTG ACA GAC AGG AGG TTC -3′
msGPR18-AS 5′- AGC CAC AGA GCG AGG CTT GG -3′
msGPR119-S 5′- CTT CTT CTA CTG TGA CAT GCT CAA GAT TGC -3′
msGPR119 -AS 5′- GCC AAT AGG CAT AGA TGA GTG GGT TG -3′
msNAPE-PLD-S 5′- GCA GCT GGT CCG TGC TAG GG -3′
msNAPE-PLD-AS 5′- CTG GCG GCT CTA GGT AAT GCT CA -3′
msFAAH-S 5′- CAA ACA GAA ACA GCC CCT GC -3′
msFAAH-AS 5′- TCC CTC CCT TCA CTT GTC CT -3′
Eyes were extracted, the lens removed, and were then immediately stored at −80°C. RNA 
was extracted using a Trizol reagent (Ambion, Austin, TX) and genomic DNA was removed 
with DNase (NEB, Bethesda, MD) following the manufacturer’s instructions. RT-PCR was 
performed using a one-step, Sybr Green amplification process (PwrSybr, Applied 
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Biosystems, Carlsbad, CA). Quantitative PCR was performed using an Eppendorf RealPlex2 
Mastercycler thermocycler.
GAPDH mRNA expression was used as an internal control for each experimental condition 
with the threshold cycle set within the linear range (10 fold above baseline). Once the 
standard critical threshold (Ct) was set, the relative expression levels for genes were 
determined. Data analysis and statistics were performed using Excel (Microsoft Corp., 
Redmond, WA) and Prism (GraphPad Software Inc., San Diego, CA) software. Values were 
compared using an unpaired t-test.
2.10 Lipidomic analysis of bovine corneal injury
The lipidomic consequences of injury were tested in the eye of the cow. The cow eye is far 
larger than the mouse eye and so better suited to reliable quantification of lipidomic changes. 
Moreover, post-mortem injury allows the separation of cornea-specific responses to injury. 
Cow eyes were obtained as above. Corneas were removed and injured by scratching then 
maintained in saline. Injured and non-injured controls were then prepared for lipidomic 
analysis.
Corneas were flash frozen in liquid nitrogen and frozen at −80°C until used for lipid 
analysis. Levels of ~35 cannabinoid-related lipids as well as arachidonic acid and several 
prostaglandin-family metabolites were measured by liquid chromatography/mass 
spectrometry from whole eyes as previously described (Bradshaw et al., 2009; Miller et al., 
2017). Briefly, corneas were homogenized, centrifuged at 19,000 × g at 24°C for 20 min and 
supernatant was collected. Compounds were isolated using a partial purification of the 25% 
organic solution. C18 solid-phase extraction columns (Agilent Technologies, Santa Clara, 
CA) were used with an elution of 100% methanol.
Samples were placed in an autosampler and held at 24°C (Agilent 1100 series autosampler, 
Palo Alto, CA) for LC/MS/MS analysis. 10–20 μL of eluents were injected for each sample 
that was rapidly separated using a C18 Zorbax reversed-phase analytical column (Agilent 
Technologies, Santa Clara, CA) to scan for individual compounds. Gradient elution (200 μL/
min) then was accomplished under pressure (Shimadzu 10AdVP pumps, Columbia, MD). 
The electrospray ionization was done using an API3000 triple quadrupole mass spectrometer 
(Applied Biosystems/DSM Sciex, Foster City, CA). A multiple reaction monitoring (MRM) 
setting on the LC/MS/MS was used to analyze levels of each compound. Analysis of the 
HPLC/MS/MS data was performed using Analyst software (Applied Biosystems Sciex). 
Chromatograms were generated by determining the retention time of analytes with a [M-1] 
or [M+1] parent peak and a fragmentation peak corresponding to the programmed values. 
The retention time was then compared with the retention time of a standard for the suspected 
compound. If the retention times matched, then the concentration of the compound was 
determined by calculating the area under the curve for the unknown and comparing it with 
the calibration curve obtained from the corresponding standards. Extraction efficiency was 
calculated relative to the standard-spiked recovery vial. Concentrations in moles per gram 
adjusted for percent recovery from the experimental condition with the untreated condition 
using a 1-way ANOVA. All statistical tests were carried out using SPSS Statistics 20 (IBM, 
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Armonk, NY, USA). Statistical significance was defined as P ≤ 0.05 and a trending effect 
was defined as 0.05 < P ≤ 0.10.
2.11 Drugs
JWH133 was purchased from Tocris Biosciences (Bristol, UK). SR144528 was purchased 
from Sigma-Aldrich (St. Louis, MO). Epithelial growth factor (EGF) was purchased from 
Invitrogen (Carlsbad, CA)
3 RESULTS
3.1 CB2R ligands induce chemorepulsion in cultured bovine corneal epithelial cells.
The CB2R agonist JWH133 (300nM) was embedded in a cube of agar and placed in a 
60mm petri dish containing recently plated bCECs. As depicted schematically in Fig 1A, the 
JWH133-containing agar block was positioned at the edge of the dish while the migration of 
epithelial cells at the center of the dish was monitored. The sample migration tracks from 
one experiment are shown in Figure 1B. Migration of cells was arrested after subsequent 
bath application (i.e. no gradient) of CB2 antagonist SR144528 (250nM, Fig. 1B, inset). We 
found that in contrast to the previously CB1 activation that induces chemoattraction 
(Murataeva et al., 2015), the CB2R agonist JWH133 induced chemorepulsion in bCECs 
(Fig. 1C–D; baseline velocity away from target (μm/min ± SEM): 0.33 ± 0.69; JWH133 
(300nM in agar): 5.10 ± 0.99; the addition of CB2R antagonist SR144528 (SR2, 250nM) to 
the bath inhibited the effects of JWH133 on migration JWH133 + SR2 (250nM bath): 1.25 
± 0.44; n=18; significant effect of JWH133 on migration using 1 way ANOVA and 
Bonferroni post-hoc test [F(3,17) = 11.8, p = 0.0003].
3.2 CB2R activation paradoxically activates both pERK and cAMP signaling
As a Gi/o-coupled receptor, CB2R would be expected to activate the MAPK pathway and 
inhibit adenylyl cyclase activity. The CB2R agonist JWH133 increased MAPK activity 
measured as ERK phosphorylation (Figure 2A; EC50 (95% CI): 78 nM (87.4–111.2); Emax 
(± SEM): 46 ± 5.6), but also modestly increased adenylyl cyclase activity even in the 
presence of forskolin (Figure 2B; EC50 6.2 nM (1.1–23.6); Emax: 36 ± 7.3). In both cases, 
the effect was blocked by including the CB2R antagonist SR144528 (SR2, 1μM; p<0.01, 
Student’s t test for 1μM SR2 vs. 1μM JWH133). We repeated the experiment without 
forskolin, since forskolin would presumably be occluding CB2R activation, and found that 
without forskolin the CB2R agonist JWH133 resulted in greater activation of adenylyl 
cyclase (Figure 2C: EC50: 7.2 nM (0.5– 17.6); Emax: 48.2 ± 6.5). The antagonist SR2 had no 
effect on its own in the pERK assay, but lowered cAMP accumulation in the absence of 
forskolin (p<0.01, Student’s t test for 1 μM SR2 vs. vehicle), suggesting that there may be 
some tonic CB2R activation of cAMP in these cells.
One potential explanation for the CB2 increase in cAMP would be coupling to Gs G 
proteins. Gs-coupling has been described for the nominally Gi/o-coupled CB1 receptor 
(Glass and Felder, 1997). We therefore revisited cAMP production after pretreatment with 
either pertussis toxin (PTX) or cholera toxin (CTX). PTX effectively blocks Gi/o signaling 
via ADP ribosylation of the alphai/o subunit (Katada and Ui, 1982). If CB2 action on cAMP 
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accumulation were Gi/o-dependent then it should be blocked by pretreatment with PTX. We 
found that it was not (Fig. 2D–E; significant effect of JWH133 on cAMP accumulation 
using 1 way ANOVA and Bonferroni post-hoc test. Figure 2D: [F(4,7) = 88.7, p = 0.02]; 
Figure 2E: [F(4,7) = 11.4, p = 0.02]). CTX by contrast ADP-ribosylates the alphas subunit 
but with the result that it constitutively activates the Gs-dependent signaling (Cassel and 
Pfeuffer, 1978). If the CB2 effects are Gs-dependent then CTX-treatment should occlude 
CB2 elevation of cAMP. Interestingly we found that not only was there no increase in cAMP 
after JWH133 treatment but instead CTX-treatment unmasked a CB2-mediated reduction in 
cAMP that was blocked by co-treatment with SR2 (Fig. 2F; significant effect of JWH133 on 
cAMP accumulation using 1 way ANOVA and Bonferroni post-hoc test. Figure 2D: [F(4,7) 
= 25.3, p = 0.046]).
3.3 Corneal injury raises levels of acylethanolamines in bovine cornea.
If endocannabinoids play a chemotaxic role in migration, then it is reasonable to expect 
measurable changes in endocannabinoid levels. We tested for changes in levels of ~35 
cannabinoid related lipids, free fatty acids and metabolites. As shown in Table 1, we found 
that there was little change in levels of any of these lipids excepting the N-acyl 
ethanolamines, all but one of which saw elevations one hour after injury (See Methods and 
Supplementary Table 1 for statistical details and values). This category includes 
arachidonoyl ethanolamine, an endogenous ligand for CB1 and CB2 receptors (Devane et 
al., 1992).
3.4 CB2R receptor activation does not alter bovine CEC proliferation
To explore whether CB2R receptors alter proliferation of bCECs, we tested several 
concentrations of CB2R agonist JWH133, all without effect. EGF (50ng/mL) in the same 
preparation induced the expected robust increase in proliferation (Fig. 3, % increase in 
proliferation for EGF (50ng/mL): 246 ± 7; *, p<0.05, 1 way ANOVA with Dunnett’s post 
hoc test vs. control). In the presence of EGF, JWH133 (1μM) did not alter cellular 
proliferation (data not shown). Neither the combination of JWH133 (1μM) + SR2 (1μM), 
nor SR2 (1μM) alone altered cellular proliferation. We conclude that CB2R receptor 
activation with JWH133 does not induce CEC proliferation.
3.5 No evidence of CB2R expression in cornea under baseline conditions in reporter 
mouse; expression is increased in injured cornea
The ongoing difficulty in obtaining credible CB2R protein staining by antibodies is widely 
recognized in the cannabinoid field, despite 20 years of efforts (Atwood and Mackie, 2010). 
We tested several commercially available CB2R antibodies for protein expression in anterior 
eye using immunohistochemistry with CB2R KO controls (data not shown, also see (Cecyre 
et al., 2014)). However, in each case the staining appeared to be non-specific as it was 
identical to the staining seen in CB2R KO mouse tissue.
CB2R reporter mice represent an alternative approach to address this question. This mouse 
model is engineered so that eGFP is co-expressed with the CB2R receptor; thus cells 
actively expressing CB2R will contain eGFP (see methods; (Lopez et al., 2018, In Press)). 
To increase signal we used an anti-eGFP antibody.
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We examined eGFP expression in uninjured cornea from the reporter mice and found that it 
is not present under baseline conditions (Fig. 4A). Upon injury, eGFP expression is 
increased in the cornea (Fig. 4C). eGFP expression appears to be somewhat more 
pronounced in superficial cells (e.g. Fig. 5A) but interestingly, we did not observe greater 
staining at the wound edge (Fig. 4C, 5A). All individual migrating cells in the wound site at 
1 hour expressed CB2R reporter.
3.6 Corneal CB2R mRNA expression is increased after injury
Using quantitative PCR (qPCR) we measured mRNA expression for cannabinoid receptors 
in injured (3 hrs) vs. uninjured eyes. We found that CB2R receptor expression was 
significantly elevated in injured relative to uninjured eyes (Fig 6A, mRNA levels in injured 
eyes (fold-change vs. uninjured (± SEM): 1.34 ± 0.11, n=12, t(22) = 2.80, p=0.01 by 
unpaired t test). CB1R expression was unaltered by injury (Fig. 6B; mRNA levels in injured 
eyes (fold-change vs. uninjured (± SEM): 0.98 ± 0.04, n=12, t(22) = 0.35, p=0.73 by 
unpaired t test).
3.7 CB1R deletion results in delayed wound closure.
We tested the consequences of cannabinoid receptor deletion on the rate of wound closure in 
an in vivo murine model of corneal wound healing. We tested the rate of wound healing in 
CB1R and CB2R KO mice. In CB1R KO mice we confirmed that CB1R deletion slows the 
rate of corneal wound healing, though by ~3 hours, somewhat less than the 8 hrs reported by 
Yang et al. (Yang et al., 2013).
3.8 CB2R deletion delays wound closure in vivo
We tested whether CB2R deletion would alter the course of wound closure. We found that 
CB2R KOs see delayed wound closure relative to wild type animals (Fig. 7B). Treatment 
with CB2R antagonist SR144528 (3mM) yielded a similar delay (Fig. 7C) as did treatment 
with the CB2R agonist JWH133 (3mM, Fig. 7D). We did not observe a sex-dependence of 
the delay in wound healing in either the CB1R or CB2R KOs (Supplemental Figure 2).
4 DISCUSSION
Our chief findings are 1) a CB2R signaling system is upregulated by injury in murine 
cornea; 2) CB1R deletion in mouse slows healing, consistent with a published finding; 3) 
CB2R deletion in mouse also slows wound closure; 4) in experiments using a different 
species, the cow, we find that levels of N-acyl ethanolamines including the eCB anandamide 
are increased upon injury in bovine cornea; 5) in epithelial cells cultured from cow eyes we 
find that CB2R activation mediates repulsive chemotaxis.
Corneal wound healing is highly choreographed, involving the directional migration of 
multiple cell types, some toward, some away, from the site of injury. It is likely that the 
movement of many of these cells is directed by chemotaxic cues. However, little is known 
about chemotaxic regulation of migration in the corneal epithelium. Yang et al. showed that 
CB1R deletion slows corneal wound healing in mice (Yang et al., 2013). This finding, taken 
together with our evidence that CB1R mediates chemotaxis in CECs offers a potential 
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mechanism for cannabinoid regulation of corneal wound healing, whereby 
endocannabinoids serve as lipid cues to direct migration of epithelial cells during the highly 
choreographed healing process. We revisited the course of wound healing in CB1R KO mice 
and confirmed the findings of Yang et al. that wound healing is slowed. The somewhat more 
rapid time course of closure seen in our experiments is likely due to the smaller wounds used 
in our preparation.
If migration of CECs is guided by a gradient of eCBs then one would expect altered levels of 
eCBs upon injury. Our finding in bovine cornea that injury elevates nearly all N-acyl 
ethanolamines tested including the CB1/CB2 endogenous ligand anandamide implicates 
these lipids as chemotaxic messengers.
Turning to CB2R, previous studies of mRNA expression in anterior eye (e.g. (Porcella et al., 
1998; Porcella et al., 2000)) and our own experiments conducted in collaboration with Dr. 
Shu-Jung Hu, suggested that CB2R mRNA was not present under baseline conditions. 
However, using quantitative PCR and a recently developed CB2R reporter mouse we 
observed an upregulation of CB2R three hours after injury. Our immunohistochemical and 
mRNA expression data are therefore consistent with a CB2R role in corneal wound healing.
Functionally, we see evidence that CB2R mediates chemorepulsion in cultured corneal 
epithelial cells. Our in vivo data shows a delay in the net course of wound healing both from 
CB2R deletion and topical treatment with CB2R antagonists. The pharmacological blockade 
indicates that the difference is not due to an adaptive developmental effect in the CB2R KO. 
Topical treatment with a CB2 agonist also slowed wound healing, a result that may seem 
counterintuitive at first. However if we assume that some key migratory events are mediated 
by a gradient of CB2 receptor ligands, then a bath application of a CB2 ligand would in fact 
eliminate the gradient (since the concentration would be the same throughout the tissue).
We have previously reported that CB1 mediates chemoattraction of CECs and that CB1 
activation reduces both cAMP levels and MAPK activity (Murataeva et al., 2015). In 
contrast CB2 activation induces chemorepulsion, elevation of cAMP levels and activation of 
MAPK. This arrangement is summarized schematically in Figure 8. Our experiments with 
pertussis toxin (PTX) and cholera toxin (CTX), which impact Gi/o and Gs signaling 
respectively, suggest that CB2 receptors predominantly signal via Gs since cholera toxin, 
which constitutively activates Gs signaling, occluded the increase in cAMP that we saw with 
CB2 agonist treatment. However it is notable that CTX treatment appeared to unmask an 
CB2-mediated lowering of cAMP. It is possible therefore that CB2 acts both via Gi/o and Gs 
in opposing directions but that Gs is dominant. In any event, it seems likely that the 
differential chemotaxic effects of these receptors are mediated by either altered cAMP, 
MAPK signaling, or both.
Epithelial cell proliferation occurs at a later stage in the process of corneal wound healing, 
as the corneal epithelial cells replenish their accustomed numbers. Yang et al (2013) 
reported that CB1R mediates an increase in CEC proliferation, a result that we were unable 
to replicate in bovine CECs (Murataeva et al., 2015). We also do not see a CB2R-mediated 
alteration of epithelial cell proliferation.
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One significant unresolved question has to do with the identity and source of the 
endocannabinoid signal. Which endocannabinoid serves as the guidance cue and what cells 
produce that endocannabinoid? The two canonical endocannabinoids are 2-arachidonoyl 
glycerol (2-AG) (Sugiura et al., 1995) and arachidonoyl ethanolamide (AEA, anandamide) 
(Devane et al., 1992), two structurally related lipids. Yang et al. measured levels of 2-AG 
and AEA in uninjured WT mouse corneas, detecting only 2-AG (Yang et al., 2013), thus 
arguing for a 2-AG role. However we find that with injury in cow eyes there is a clear and 
specific increase in the levels of acyl-ethanolamines, including AEA, while levels of other 
cannabinoid-related lipids including 2-AG remain unaltered. Moreover, we have tested 
mouse corneas for expression of cannabinoid-related lipids and do detect AEA (data not 
shown), suggesting that the difference is due to differential detection limits (since AEA 
levels are often an order of magnitude lower than 2-AG (Cravatt et al., 2001)) rather than a 
species difference. Endocannabinoids are lipids that are produced ‘on demand’ 
enzymatically (Murataeva et al., 2013), so it is not surprising that levels of these should rise 
as a group. Synthesis of acyl-ethanolamines likely occurs via activity of NAPE-PLD 
(Leishman et al., 2016), message for which we have previously detected in bovine cornea 
(Murataeva et al., 2015). We have also shown that NAPE-PLD knockout mice see 
diminished levels of AEA in mouse eye (Miller et al., 2016). Our results therefore support a 
role for AEA over 2-AG in wound healing, and moreover suggest that the synthesis of acyl-
ethanolamines occurs locally within the cornea rather than deriving from extraocular sources 
such as the lacrimal glands. However it should be stressed that there may be significant 
species differences in cannabinoid regulation of corneal function between the mouse and 
cow, not least due to the considerable difference in size.
To our knowledge this is the first evidence for a signaling system that underlies 
chemorepulsion in corneal epithelial cells. Though CB2R appears to be intimately involved 
in both wound healing and migration, additional work will be required to formulate a 
coherent model of a CB2R role in regulation of wound healing. In particular it will be 
essential to determine the circuitry of cannabinoid signaling. Which cannabinoids are 
produced under what circumstances by which cells. Our results from post-mortem injured 
cornea implicate local production of acyl-ethanolamines in early stage wound healing but 
this does not rule out additional contributions from extra-ocular sources such as the lacrimal 
glands or from the immune cells that migrate to the site of injury.
It may seem odd at first two related receptors should have opposing actions, perhaps even in 
the same cells. It is possible, however, that the balance of push/pull signals allows for a more 
fine-tuned migratory cue. Cells would migrate until they reach a point where the push/pull 
ratio is in balance, and loiter there, rather than simply migrating toward or away from the 
source.
Given the immune component in corneal healing, it may not be a coincidence that CB2R 
plays this role since CB2R is a receptor long associated with immune responses (Atwood 
and Mackie, 2010). Neutrophils responding to bacterial ingress outside the wound or 
leukocytes accumulating under the basement membrane may themselves respond to such 
cues (reviewed in (Cabral et al., 2015)) or might produce a repulsive cue, thereby allowing a 
flexible response to bacterial load in the site of injury.
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One major question is to what extent these findings may be generalizable to other species 
and tissues. It is tempting to speculate that chemotaxic regulation of cell migration may be 
involved in wound healing in related tissues such as skin, but the cornea has unusual 
properties that may limit generalizability of our findings. In contrast to skin, the cornea is 
avascular and experiences major differences in terms of blood intrusion, coagulation, 
inflammation, scarring, and the overall timing of wound healing. It is therefore possible but 
not certain that this cannabinoid receptor-dependent signaling system is employed in other 
epithelial tissues that undergo responses to injury such as skin and the lining of the gut. 
Nearly all cells migrate at some point in their existence and so it is possible that 
cannabinoid-based migration cues will be found to play roles in other tissues. CB1 receptors 
are widely distributed in the brain and body (Buckley et al., 1998; Herkenham et al., 1990). 
However since the CB2 role described here required pathology-induced upregulation, any 
CB2 role in other tissues may also be restricted to pathological and/or immune-related 
conditions. There are tissues such as bone that express both receptors without the 
requirement for pathology; but taking the example of bone (Zimmer, 2016) CB1 and CB2 
already have defined roles in bone remodeling. The implications of our in vivo experiments 
in mice, which have considerable size and structural differences in their cornea relative to 
other species such as humans, may also be limited, particularly when one considers that 
there are significant differences in wound healing even across mouse strains (Pal-Ghosh et 
al., 2008).
In summary, we find that cannabinoid CB2R receptors are upregulated upon injury in the 
mouse and that deletion of either cannabinoid CB1R or CB2R receptors impairs the normal 
course of healing. Moreover, we find that these receptors mediate chemorepulsion in 
cultured bovine corneal epithelial cells and that endocannabinoids levels rise with injury in 
bovine corneal explants. Our results indicate that CB2R receptors are involved in the normal 
course of healing, perhaps via regulation of chemotaxis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements:
This work was supported in part by a grant from the National Institutes of Health [RO1-EY24625, AS].
Abbreviations:
ABHD12 a/b hydrolase domain containing 12
bCECs bovinecorneal epithelial cells
CB1 cannabinoid receptor 1
CB2 cannabinoid receptor 2
GFP green fluorescent protein
DMSO dimethylsulfoxide
Murataeva et al. Page 12













FRET fluorescence resonance energy transfer
LITERATURE CITED
Atwood BK, Mackie K, 2010 CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160, 
467–479. [PubMed: 20590558] 
Bradshaw HB, Rimmerman N, Hu SS, Burstein S, Walker JM, 2009 Novel endogenous N-acyl 
glycines identification and characterization. Vitam Horm 81, 191–205. [PubMed: 19647113] 
Buckley NE, Hansson S, Harta G, Mezey E, 1998 Expression of the CB1 and CB2 receptor messenger 
RNAs during embryonic development in the rat. Neuroscience 82, 1131–1149. [PubMed: 9466436] 
Cabral GA, Ferreira GA, Jamerson MJ, 2015 Endocannabinoids and the Immune System in Health and 
Disease. Handb Exp Pharmacol 231, 185–211. [PubMed: 26408161] 
Cairns EA, Toguri JT, Porter RF, Szczesniak AM, Kelly ME, 2015 Seeing over the horizon - targeting 
the endocannabinoid system for the treatment of ocular disease. J Basic Clin Physiol Pharmacol.
Cassel D, Pfeuffer T, 1978 Mechanism of cholera toxin action: covalent modification of the guanyl 
nucleotide-binding protein of the adenylate cyclase system. Proc Natl Acad Sci U S A 75, 2669–
2673. [PubMed: 208069] 
Cecyre B, Thomas S, Ptito M, Casanova C, Bouchard JF, 2014 Evaluation of the specificity of 
antibodies raised against cannabinoid receptor type 2 in the mouse retina. Naunyn Schmiedebergs 
Arch Pharmacol 387, 175–184. [PubMed: 24185999] 
Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH, 2001 
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking 
fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98, 9371–9376. [PubMed: 11470906] 
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, 
Etinger A, Mechoulam R, 1992 Isolation and structure of a brain constituent that binds to the 
cannabinoid receptor. Science 258, 1946–1949. [PubMed: 1470919] 
Fiskerstrand T, H’Mida-Ben Brahim D, Johansson S, M’Zahem A, Haukanes BI, Drouot N, 
Zimmermann J, Cole AJ, Vedeler C, Bredrup C, Assoum M, Tazir M, Klockgether T, Hamri A, 
Steen VM, Boman H, Bindoff LA, Koenig M, Knappskog PM, 2010 Mutations in ABHD12 cause 
the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism. Am J 
Hum Genet 87, 410–417. [PubMed: 20797687] 
Gaoni Y, Mechoulam R, 1964 Isolation, structure and partial synthesis of an active constituent of 
hashish. J Am Chem Soc 86, 1646–1647.
Ghosh S, Preet A, Groopman JE, Ganju RK, 2006 Cannabinoid receptor CB2 modulates the CXCL12/
CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 43, 2169–2179. [PubMed: 
16503355] 
Glass M, Felder CC, 1997 Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors 
augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J 
Neurosci 17, 5327–5333. [PubMed: 9204917] 
He F, Song ZH, 2007 Molecular and cellular changes induced by the activation of CB2 cannabinoid 
receptors in trabecular meshwork cells. Mol Vis 13, 1348–1356. [PubMed: 17679938] 
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC, 1990 
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87, 1932–1936. [PubMed: 
2308954] 
Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ, 2004 Cannabinoid 
physiology and pharmacology: 30 years of progress. Neuropharmacology 47 Suppl 1, 345–358. 
[PubMed: 15464149] 
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M, 2009 Endocannabinoid-
mediated control of synaptic transmission. Physiol Rev 89, 309–380. [PubMed: 19126760] 
Katada T, Ui M, 1982 ADP ribosylation of the specific membrane protein of C6 cells by islet-
activating protein associated with modification of adenylate cyclase activity. J Biol Chem 257, 
7210–7216. [PubMed: 7200979] 
Murataeva et al. Page 13













Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, 
Roques BP, Vassart G, Fratta W, Parmentier M, 1999 Unresponsiveness to cannabinoids and 
reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401–404. 
[PubMed: 9888857] 
Leishman E, Mackie K, Luquet S, Bradshaw HB, 2016 Lipidomics profile of a NAPE-PLD KO mouse 
provides evidence of a broader role of this enzyme in lipid metabolism in the brain. Biochim 
Biophys Acta 1861, 491–500. [PubMed: 26956082] 
Li SS, Wang LL, Liu M, Jiang SK, Zhang M, Tian ZL, Wang M, Li JY, Zhao R, Guan DW, 2016 
Cannabinoid CB(2) receptors are involved in the regulation of fibrogenesis during skin wound 
repair in mice. Mol Med Rep 13, 3441–3450. [PubMed: 26935001] 
Lopez A, Aparicio N, Pazos MR, Grande MT, Barreda-Manso MA, Benito I, Vazquez C, Amores M, 
Ruiz-Perez G, Garcia-Garcia E, Beatka M, Tolon RM, Dittel BN, Hillard C, Romero J, 2018, In 
Press. Cannabinoid CB2 receptors in the mouse brain: Relevance for Alzheimer’s disease. Journal 
of Neuroinflammation.
Lu Q, Straiker A, Maguire G, 2000 Expression of CB2 cannabinoid receptor mRNA in adult rat retina. 
Vis Neurosci 17, 91–95. [PubMed: 10750830] 
Meijering E, Dzyubachyk O, Smal I, 2012 Methods for cell and particle tracking. Methods Enzymol 
504, 183–200. [PubMed: 22264535] 
Miller S, Hu SS, Leishman E, Morgan D, Wager-Miller J, Mackie K, Bradshaw HB, Straiker A, 2017 
A GPR119 signaling system in the murine eye regulates intraocular pressure in a sex-dependent 
manner. Invest Ophthalmol Vis Sci 58, 2930–2938. [PubMed: 28593245] 
Miller S, Leishman E, Oehler O, Daily L, Murataeva N, Wager-Miller J, Bradshaw H, Straiker A, 2016 
Evidence for a GPR18 role in diurnal regulation of intraocular pressure. Invest Ophthalmol Vis Sci 
57, 6419–6426. [PubMed: 27893106] 
Munro S, Thomas KL, Abu-Shaar M, 1993 Molecular characterization of a peripheral receptor for 
cannabinoids. Nature 365, 61–65. [PubMed: 7689702] 
Murataeva N, Dhopeshwarkar A, Yin D, Mitjavila J, Bradshaw H, Straiker A, Mackie K, 2016 
Where’s my entourage? The curious case of 2-oleoylglycerol, 2-linolenoylglycerol, and 2-
palmitoylglycerol.Pharmacol Res 110, 173–180. [PubMed: 27117667] 
Murataeva N, Li S, Oehler O, Miller S, Dhopeshwarkar A, Hu SS, Bonanno JA, Bradshaw H, Mackie 
K, McHugh D, Straiker A, 2015 Cannabinoid-induced chemotaxis in bovine corneal epithelial 
cells. Invest Ophthalmol Vis Sci 56, 3304–3313. [PubMed: 26024113] 
Murataeva N, Mackie K, Straiker A, 2012 The CB2-preferring agonist JWH015 also potently and 
efficaciously activates CB1 in autaptic hippocampal neurons. Pharmacol Res 66, 437–442. 
[PubMed: 22921769] 
Murataeva N, Straiker A, Mackie K, 2013 Parsing the players: 2-AG synthesis and degradation in the 
CNS. Br J Pharmacol 171, 1379–1391.
Pal-Ghosh S, Tadvalkar G, Jurjus RA, Zieske JD, Stepp MA, 2008 BALB/c and C57BL6 mouse strains 
vary in their ability to heal corneal epithelial debridement wounds. Exp Eye Res 87, 478–486. 
[PubMed: 18809399] 
Porcella A, Casellas P, Gessa GL, Pani L, 1998 Cannabinoid receptor CB1 mRNA is highly expressed 
in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Brain Res Mol 
Brain Res 58, 240–245. [PubMed: 9685662] 
Porcella A, Maxia C, Gessa GL, Pani L, 2000 The human eye expresses high levels of CB1 
cannabinoid receptor mRNA and protein. Eur J Neurosci 12, 1123–1127. [PubMed: 10762343] 
Straiker A, Stella N, Piomelli D, Mackie K, Karten HJ, Maguire G, 1999a Cannabinoid CB1 receptors 
and ligands in vertebrate retina: localization and function of an endogenous signaling system. Proc 
Natl Acad Sci U S A 96, 14565–14570. [PubMed: 10588745] 
Straiker AJ, Maguire G, Mackie K, Lindsey J, 1999b Localization of cannabinoid CB1 receptors in the 
human anterior eye and retina. Invest Ophthalmol Vis Sci 40, 2442–2448. [PubMed: 10476817] 
Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K, 1995 2-
Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem 
Biophys Res Commun 215, 89–97. [PubMed: 7575630] 
Murataeva et al. Page 14













Wang LL, Zhao R, Li JY, Li SS, Liu M, Wang M, Zhang MZ, Dong WW, Jiang SK, Zhang M, Tian 
ZL, Liu CS, Guan DW, 2016 Pharmacological activation of cannabinoid 2 receptor attenuates 
inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. Eur J 
Pharmacol 786, 128–136. [PubMed: 27268717] 
Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S, 2005 Differential 
expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound 
healing. Gastroenterology 129, 437–453. [PubMed: 16083701] 
Yang Y, Yang H, Wang Z, Varadaraj K, Kumari SS, Mergler S, Okada Y, Saika S, Kingsley PJ, Marnett 
LJ, Reinach PS, 2013 Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 1-
induced inflammatory responses to corneal injury. Cell Signal 25, 501–511. [PubMed: 23142606] 
Zheng JL, Yu TS, Li XN, Fan YY, Ma WX, Du Y, Zhao R, Guan DW, 2012 Cannabinoid receptor type 
2 is time-dependently expressed during skin wound healing in mice. Int J Legal Med 126, 807–
814. [PubMed: 22814434] 
Zhong L, Geng L, Njie Y, Feng W, Song ZH, 2005 CB2 cannabinoid receptors in trabecular meshwork 
cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest 
Ophthalmol Vis Sci 46, 1988–1992. [PubMed: 15914613] 
Zimmer A, 2016 A collaboration investigating endocannabinoid signalling in brain and bone. J Basic 
Clin Physiol Pharmacol 27, 229–235. [PubMed: 26887036] 
Murataeva et al. Page 15














• Functional cannabinoid CB2 receptors are upregulated upon injury in corneal 
epithelium
• CB2 receptor deletion impairs the course of wound healing.
• CB2 receptors mediate chemorepulsion in corneal epithelial cells.
• CB2 receptors do not alter the epithelial cell proliferation.
• Findings suggest that like CB1, cannabinoid CB2 receptors play a role in the 
course of wound healing, but via chemorepulsion.
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Figure 1. CB2R activation mediates chemorepulsion in bovine corneal epithelial cells.
A) Schematic illustrating in-dish migration assay with drug- embedded agar block. B) Cell 
tracking from representative experiment. Direction of agar block indicated by arrow. Inset 
shows subsequent migration of same cells after bath application of SR2, with starting points 
normalized to the origin to facilitate comparison. C) Net distance traveled relative to agar 
cube containing JWH133 (300nM), before and after bath application of CB2R antagonist 
SR144528 (SR2, 250nM). D) Bar graph summarizes velocities away from target. *, p<0.05, 
**, p<0.01, One-way ANOVA with Bonferroni post hoc test.
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Figure 2. CB2R activation increases MAPK signaling and activates adenylyl cyclase in bovine 
CECs.
A) phosphoERK (pERK) levels are increased in a concentration-dependent manner by 
CB2R agonist JWH133. This effect is blocked by CB2R antagonist SR144528 (SR2, 1μM, 
p<0.001, Student’s t test for 1μM concentrations). B) JWH133 modestly increases adenylyl 
cyclase activity even in the presence of adenylyl cyclase activator forskolin. C) In the 
absence of forskolin, JWH133 induces an increase in cAMP. SR2 (1μM) alone substantially 
lowers cAMP accumulation, indicating tonic activity or off target effects. D-F) cAMP 
accumulation was revisited with pertussis toxin (PTX) or cholera toxin (CTX) pretreatment. 
D) Control shows increase with 1uM JWH133 as expected from prior results. E) Same 
experiment after PTX pretreatment shows that effect is maintained. F) CTX pretreatment 
however unmasked a suppression of cAMP production. *, p<0.05, 1 way ANOVA with 
Bonferroni post hoc test.
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Fig. 3: JWH133 does not enhance proliferation of bCECs.
In a proliferation assay, JWH133 (100nM and 1 μM) and SR2 (1 μM) do not alter bCEC 
proliferation. 14 P>0.05, 1 way ANOVA with Bonferroni post hoc vs. control. EGF 
increases proliferation significantly p<0.05 1 way ANOVA with Dunnett’s post hoc vs. 
control.
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Figure 4. eGFP expression in cornea of reporter mice.
A) eGFP expression in uninjured corneas of CB2R reporter mice stained with anti-GFP 
antibody. A1) phalloidin staining outlines epithelial cells. A2) Corresponding DIC image. B) 
Injured WT control staining same anti-GFP antibody. B1, B2 as in A. Arrow in B2 shows 
region of wound. C) GFP staining in injured CB2R reporter cornea. C1, C2 as in A. Arrow 
in C2 shows region of wound. Scale bars: A) 35μm; B-C) 40μm.
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Figure 5. eGFP immunoreactivity in epithelial cells of injured cornea.
A) CB2R reporter expression in cells at wound edge at 1 hour post-injury. Arrow shows 
wound area. B) CB2R reporter expression in individual cells that have migrated into the 
wound site. Scale bars: A) 30 μm; B) 25 μm.
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Figure 6. CB2R mRNA expression is upregulated in mouse eye after corneal injury.
Using quantitative PCR (qPCR) we tested mRNA expression for cannabinoid receptors in 
injured (3 hrs) vs. uninjured enucleated eyes. A) CB2R receptor expression was elevated in 
injured relative to uninjured eyes. B) CB1 expression was unaltered by injury.*, p<0.05 by 
unpaired t-test.
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Figure 7. Deletion of CB1 and CB2R cannabinoid receptors differentially alters the rate of 
wound healing in mice.
A) WT mice heal fully by 12–15 hours. CB1R KOs see delayed wound closure relative to 
CD1 strain controls. B) CB2R KOs also see delayed wound closure relative to C57Bl/6 
(C57) strain controls. C) Treatment with CB2R antagonist SR144528 (3mM) mimics the 
delay in healing. D) CB2R agonist JWH133 also results in a similar time course to that for 
CB2R KOs. Lower panel: Sample time courses from WT, CB1R KO and CB2R KO eyes. *, 
p<0.05, **, p<0.01, ***, p<0.001, 2-way ANOVA with Bonferroni post hoc test.
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Figure 8. Schematic of opposing CB1 and CB2 regulation of epithelial cell chemotaxis.
Diagram depicts contrasting cAMP and MAPK signaling of CB1 and CB2 receptor as well 
as their opposing effects on chemotaxis.
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Table 1.
Lipidomic analysis of endocannabinoids after 1 hour injury in bovine cornea.
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